Spring Bank

@SpringBankPharm

Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharma company developing a novel class of therapeutics using our SMNH chemistry platform.

Vrijeme pridruživanja: prosinac 2011.

Medijski sadržaj

  1. 19. pro 2019.

    Designed to resemble naturally occurring nucleotides and nucleic acids in the body, our SMNH compounds cause no observed non-specific immune response and target a broad range of disease, including viral diseases and cancers. :

  2. 17. pro 2019.

    Citing our two clinical programs, multiple data readouts, high quality partners and a cash runway beyond 2021, notes that Spring Bank could be undervalued. Read more. : FLS Disclaimer:

  3. 16. pro 2019.

    Inarigivir selectively activates within cells infected with , inhibiting viral replication and causing the induction of intracellular interferon signaling pathways for antiviral defense. Learn more about this mechanism here :

  4. 13. pro 2019.

    Among our pipeline of compounds, we plan to focus most on the inarigivir compound for treatment and SB 11285 for applications. See our full pipeline here. :

  5. 12. pro 2019.

    We design our proprietary SMNH compounds to bind specifically to their intended proteins, producing high therapeutic benefit over current therapies. We are committed to the highest standards of scientific excellence and integrity :

  6. 11. pro 2019.

    STimulator of INterferon Genes, or STING, is a protein that can activate the body’s innate immune system. SB 11285 is an agent that activates the STING pathway currently being developed for the treatment of some cancers. :

  7. 10. pro 2019.

    We released results from the first cohort of the clinical trial examining the co-administration of the low dose of inarigivir 50mg and the nucleoside analog, Vemlidy®. . Learn more about this trial here from :

  8. 9. pro 2019.

    Novel Small Molecule Drug Discovery Platform Harnesses Immune System to Defeat Cancers, Viral Infections & Inflammatory Diseases. Read the article from Dr. Kris Iyer in Drug Development & Delivery (FLS Disclaimer: ):

  9. 27. stu 2019.

    Designed to resemble naturally occurring nucleotides and nucleic acids in the body, our SMNH compounds are relatively easy to manufacture and include no observed non-specific immune response :

  10. 25. stu 2019.

    We are a clinical-stage company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid platform. Want more investment-relevant info? Check here :

  11. 22. stu 2019.

    Learn all about our development pipelines in our three main therapeutic areas: , , and inflammatory diseases :

  12. 21. stu 2019.

    At Spring Bank, we are committed to the highest standards of scientific excellence and integrity for the benefit of patients and the medical community. Learn more about our mission :

  13. 20. stu 2019.

    Our small molecule nucleic acid hybrid compounds act directly on target proteins, and have the potential to be used as part of combinatorial treatments, for example in with other antivirals :

  14. 18. stu 2019.

    Since inception, we have sought to apply our small molecule nucleic acid hybrid chemistry platform toward the discovery and development of novel drugs. The work has culminated in inarigivir, which is now being studied in Phase 2 clinical trials :

  15. 15. stu 2019.

    Want to dive deep into the science and documentation behind our technology? Take a look at our publications :

  16. 14. stu 2019.

    STimulator of INterferon Genes, or STING, is a protein that has the power to activate the body’s innate immune system. SB 11285 is a potent immunotherapeutic agent that activates the STING pathway. Read more about it here. :

  17. 13. stu 2019.

    We are focusing the development of our two most advanced product candidates, inarigivir and SB 11285, on the treatment of and various cancers respectively :

  18. 12. stu 2019.

    Did you know that attaining a functional cure for chronic will likely require modulation of the immune system? Our product candidate inarigivir is being developed with this in mind. Learn more about it :

  19. 8. stu 2019.

    At Spring Bank, we always have confidence in our Board of Directors, given that it is made up of a number of highly accomplished and experienced individuals who each bring their own expertise to the table. Get to know our Board here :

  20. 7. stu 2019.

    Our SMNH compounds target a broad range of diseases, including and oncological diseases , and our SMNH technology limits the likelihood of drug-drug interactions :

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·